New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Former Nickerson basketball star Ava Jones is speaking out about her cancer diagnosis months after a man was sentenced to ...

Members of the Leukemia and Lymphoma Society discussed the importance of educating others, fundraising and spreading ...

Shares of Tempus AI (TEM) are rising 5% in pre-market trading after surging 13% yesterday. The healthcare-focused AI stock ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Thursday after the company announced a collaboration with the ...